Revelation Biosciences, Inc. (REVB) Income Statement
REVB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsREVB revenue and net income
REVB profit margins
REVB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
REVB quarterly EPS vs estimates
Revelation Biosciences beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.88).
REVB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $95.8M | $85.1M | $74.0M | $48.8M |
| Cost of revenue | $27,058 | $27,923 | $25,049 | $40,008 | $69,166 | — | $4.9M | $0 | $0 | $0 |
| Gross profit | −$27,058 | −$27,923 | −$25,049 | −$40,008 | −$69,166 | — | $90.9M | $81.0M | $70.8M | $45.2M |
| Research & development | $4.1M | $3.5M | $4.1M | $5.4M | $6.9M | $2,561 | — | — | — | — |
| Sales, general & admin | $5.0M | $4.4M | $4.5M | $5.5M | $5.0M | $145,492 | $36.3M | $34.0M | $31.3M | $21.5M |
| Total operating expenses | $9.1M | $8.0M | $8.7M | $10.9M | $12.0M | $145,492 | $3,638 | $42.1M | $38.1M | $26.5M |
| Operating income | −$9.1M | −$8.0M | −$8.7M | −$10.9M | −$12.0M | −$145,492 | −$3,638 | $38.9M | $32.7M | $18.8M |
| Interest income | — | — | — | — | — | — | $129.3M | $107.0M | $88.4M | $57.1M |
| Interest expense | — | — | — | $34,962 | $41,759 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$8.9M | −$15.0M | −$120,254 | −$10.8M | −$12.0M | −$136,408 | −$3,638 | $37.1M | $29.8M | $14.9M |
| Income taxes | — | — | $1 | −$34,962 | −$219,776 | −$3,796 | −$171,860 | $9.4M | $13.6M | $6.1M |
| Net income | −$8.9M | −$15.0M | −$120,254 | −$10.8M | −$12.0M | −$136,408 | −$3,638 | $27.6M | $16.3M | $8.8M |
| EBITDA | −$9.0M | −$7.9M | −$8.6M | −$10.8M | −$11.9M | −$145,492 | −$3,638 | — | — | — |
| EPS (diluted) | −$41.06 | −$1623.54 | −$4349.04 | −$143944.42 | −$29511.14 | −$35941.58 | $2.61 | $1.24 | — | — |
| Gross margin | — | — | — | — | — | — | 94.9% | 95.1% | 95.7% | 92.7% |
| Operating margin | — | — | — | — | — | — | −0.0% | 45.7% | 44.2% | 38.4% |
| Net margin | — | — | — | — | — | — | −0.0% | 32.5% | 22.0% | 18.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $26,964 | $0 | $0 | $0 | $37,574 | $0 |
| Cost of revenue | — | $7,203 | $5,852 | $6,765 | $7,220 | $7,221 | $13,482 | $7,220 | $7,220 | $6,262 | $18,787 | $6,262 |
| Gross profit | — | −$7,203 | −$5,852 | −$6,765 | −$7,220 | −$7,221 | $13,482 | −$7,220 | −$7,220 | −$6,262 | $18,787 | −$6,262 |
| Research & development | $1.9M | $1.4M | $964,190 | $922,857 | $1.3M | $858,830 | $605,504 | $830,981 | $1.4M | $717,582 | $1.1M | $1.7M |
| Sales, general & admin | $1.7M | $1.7M | $1.6M | $1.0M | $1.1M | $1.2M | $1.2M | $965,705 | $1.1M | $1.2M | $1.3M | $1.1M |
| Total operating expenses | $3.7M | $3.1M | $2.6M | $1.9M | $2.5M | $2.1M | $1.8M | $1.8M | $2.5M | $1.9M | $2.3M | $2.8M |
| Operating income | −$3.7M | −$3.1M | −$2.6M | −$1.9M | −$2.5M | −$2.1M | −$1.8M | −$1.8M | −$2.5M | −$1.9M | −$2.3M | −$2.8M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $7.8M | — |
| Income before taxes | −$3.3M | −$3.0M | −$2.5M | −$1.9M | −$2.4M | −$2.1M | −$1.7M | −$2.2M | −$8.4M | −$2.7M | −$2.2M | −$2.6M |
| Income taxes | — | — | −$85 | — | — | — | $2 | — | — | −$2 | $8.3M | −$92,561 |
| Net income | −$3.3M | −$3.0M | −$2.5M | −$1.9M | −$2.4M | −$2.1M | −$1.7M | −$2.2M | −$8.4M | −$2.7M | −$2.2M | −$2.6M |
| EBITDA | −$3.3M | −$3.1M | −$2.6M | −$1.9M | −$2.5M | −$2.1M | −$1.7M | −$1.8M | −$2.5M | −$1.9M | −$2.3M | −$2.8M |
| EPS (diluted) | −$0.87 | −$2.71 | −$1.65 | −$7.08 | −$7.01 | −$25.32 | −$4.98 | −$161.28 | −$984.96 | −$472.32 | −$8.33 | −$2488.78 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 50.0% | — |
| Operating margin | — | — | — | — | — | — | −6,504.6% | — | — | — | −6,190.2% | — |
| Net margin | — | — | — | — | — | — | −6,400.1% | — | — | — | −5,862.8% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in REVB's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
REVB financial results
Revelation Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $8.9 million. Diluted earnings per share came to −$41.06.
See the REVB stock overview for the latest quote and news, or the REVB chart for price history and technical indicators.
REVB income statement FAQ
Does Revelation Biosciences have revenue?
Revelation Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Revelation Biosciences profitable?
No. Revelation Biosciences reported a net loss of $8.9 million in fiscal 2025.
How much does Revelation Biosciences spend on research and development?
Revelation Biosciences spent $4.1 million on research and development in fiscal 2025.
What are Revelation Biosciences's earnings per share?
Revelation Biosciences earned $-41.06 per diluted share in fiscal 2025, compared with $-1623.54 a year earlier.
When will Revelation Biosciences report its next earnings?
Revelation Biosciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Revelation Biosciences's fiscal year end?
Revelation Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.